Atosiban
Atosiban by Zyntex is a high-purity synthetic peptide and oxytocin receptor antagonist (CAS 90779-69-4). It is a critical active pharmaceutical ingredient (API) used in obstetrics to delay imminent preterm birth by inhibiting uterine contractions.
Description
Comprehensive Product Overview of Atosiban
Exceptional receptor specificity and a favorable safety profile provide a major advantage in modern obstetric care. Atosiban works by decreasing the frequency of contractions and uterine muscle tone, making it a “gold standard” in the manufacturing of emergency tocolytics. It helps clinical teams gain critical time for the administration of corticosteroids or for maternal transfer to specialized centers. For instance, it is a primary component in producing hospital-grade infusions for expectant mothers between 24 and 33 weeks of gestation. Consequently, it enhances the chances of reducing neonatal morbidity. As a result, Zyntex ensures ultra-high peptide purity and rigorous control over related impurities for our supply. This ensures maximum biological activity and safety in your manufacturing cycles.
Moreover, Zyntex supplies high-grade Atosiban for advanced reproductive medicine and clinical research. This compound acts as a critical tool in studying the mechanisms of uterine contractility and oxytocin signaling. It pushes the boundaries of neonatal health by offering a targeted alternative to traditional beta-mimetics or calcium channel blockers. At the same time, it serves as a vital active in the development of refined protocols for managing preterm labor. In short, our product serves as a dependable “uterine quiescence modulator.” It supports both the acute requirements of labor and delivery units and the long-term R&D goals of pharmaceutical innovators.
Recently, scientific interest in Atosiban for its role in improving pregnancy outcomes in assisted reproductive technology (ART), specifically during embryo transfer, has grown. It provides high efficacy in reducing uterine activity that might otherwise interfere with implantation. Because of this, Zyntex offers specialized lyophilized formats with verified chemical profiles to meet international pharmacopeia standards. These formats suit modern sterile filling technology and advanced injectable R&D. Ultimately, choosing Zyntex secures a reliable and transparent pharmaceutical supply chain. We balance complex peptide synthesis expertise with rigorous batch-to-batch HPLC and mass spectrometry quality monitoring. To conclude, our commitment ensures your manufacturing processes achieve the highest levels of performance and stability.
Key Industrial Applications for Atosiban
This essential tocolytic peptide is vital in these four sectors:
🤰 Obstetrics & Gynecology
Primary API for delaying imminent preterm birth. Thus, it is a cornerstone of emergency maternity ward pharmaceutical stock.
💉 Injectable Formulations
Used in concentrated solutions for intravenous bolus and infusion. Consequently, it is vital for acute hospital-based tocolytic therapy.
🧫 Reproductive Research
Primary ingredient in studies focused on oxytocin receptor modulation. Undoubtedly, it is essential for advanced fertility and pregnancy research.
🔬 Peptide Synthesis R&D
Acts as a reference standard for complex nonapeptide manufacturing. Specifically, it supports the development of new peptide-based drugs.
Technical Specifications
| Parameter | Standard Value |
|---|---|
| Product Name | Atosiban Acetate |
| Molecular Formula | $C_{43}H_{67}N_{11}O_{12}S_{2}$ |
| Purity (HPLC) | ≥ 99.0% |
| CAS Number | 90779-69-4 |
⚠️ Safety & Handling: Atosiban API is intended for professional pharmaceutical use only. Therefore, handle with care using appropriate PPE in a sterile or controlled laboratory environment. Potential side effects in clinical use include nausea and headache; handle concentrated powder to avoid accidental inhalation. Store in a freezer at -20°C, protected from light and moisture, to maintain the long-term stability of the peptide chain.
